FBRX

Company Overview — What Does Forte Biosciences, Inc. Do?

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas. Forte Biosciences, Inc. (FBRX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Paul A. Wagner and employs approximately 5 people. With a market capitalization of $322M, FBRX is one of the notable companies in the Healthcare sector.

Forte Biosciences, Inc. (FBRX) Stock Rating — Reduce (April 2026)

As of April 2026, Forte Biosciences, Inc. receives a Reduce rating with a composite score of 35.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.FBRX ranks #2,616 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Forte Biosciences, Inc. ranks #343 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

FBRX Stock Price and 52-Week Range

Forte Biosciences, Inc. (FBRX) currently trades at $35.09. The stock gained $1.19 (3.5%) in the most recent trading session. The 52-week high for FBRX is $35.62, which means the stock is currently trading -1.5% from its annual peak. The 52-week low is $4.90, putting the stock 616.1% above its annual trough. Recent trading volume was 935K shares, suggesting relatively thin trading activity.

Is FBRX Overvalued or Undervalued? — Valuation Analysis

Forte Biosciences, Inc. (FBRX) carries a value factor score of 18/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.96x, versus the sector average of 2.75x. The price-to-sales ratio is 33.46x, compared to 1.66x for the average Healthcare stock.

At current multiples, Forte Biosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Forte Biosciences, Inc. Profitability — ROE, Margins, and Quality Score

Forte Biosciences, Inc. (FBRX) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -86.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -64.0% versus the sector average of -33.1%.

The operating margin is -2602.5% (sector: -66.1%). Net profit margin stands at -2555.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

FBRX Debt, Balance Sheet, and Financial Health

Forte Biosciences, Inc. has a debt-to-equity ratio of 36.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.88x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $93M.

FBRX has a beta of 0.80, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Forte Biosciences, Inc. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Forte Biosciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Forte Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-4.71. Net income for the quarter was $-53M. Operating income came in at $-55M.

In FY 2025, Forte Biosciences, Inc. reported revenue of $3M and earnings per share (EPS) of $-4.71. Net income for the quarter was $-69M. Revenue grew 106.6% year-over-year compared to FY 2024. Operating income came in at $-71M.

In Q3 2025, Forte Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.99. Net income for the quarter was $-18M. Operating income came in at $-18M.

In Q2 2025, Forte Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.96. Net income for the quarter was $-11M. Operating income came in at $-12M.

Over the past 8 quarters, Forte Biosciences, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing FBRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

FBRX Dividend Yield and Income Analysis

Forte Biosciences, Inc. (FBRX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

FBRX Momentum and Technical Analysis Profile

Forte Biosciences, Inc. (FBRX) has a momentum factor score of 68/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.

FBRX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Forte Biosciences, Inc. (FBRX) ranks #343 out of 838 stocks based on the Blank Capital composite score. This places FBRX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing FBRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full FBRX vs S&P 500 (SPY) comparison to assess how Forte Biosciences, Inc. stacks up against the broader market across all factor dimensions.

FBRX Next Earnings Date

No upcoming earnings date has been announced for Forte Biosciences, Inc. (FBRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy FBRX? — Investment Thesis Summary

The quantitative profile for Forte Biosciences, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 18/100 indicates premium valuation. Price momentum is positive at 68/100, suggesting the trend favors buyers. High volatility (stability score 35/100) increases portfolio risk.

In summary, Forte Biosciences, Inc. (FBRX) earns a Reduce rating with a composite score of 35.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on FBRX stock.

Related Resources for FBRX Investors

Explore more research and tools: FBRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare FBRX head-to-head with peers: FBRX vs AZN, FBRX vs SLGL, FBRX vs VMD.